Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
BRAF+
•
Langerhans Cell Histiocytosis
Do you recommend using BRAFV600E mutation status to risk stratify treatment for a pediatric patient with langerhans cell histiocytosis?
Answer from: at Community Practice
It’s certainly useful information. Even if you don’t use a BRAF inhibitor as first line therapy, you will have that option in your back pocket.
Sign in or Register to read more
7749
Related Questions
In a patient hospitalized for several days with a refractory pain crisis would you ever consider transfusion, either simple or possibly exchange in an attempt to get the patient over the crisis?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
How would you approach patients with primary cardiac sarcomas for adjuvant systemic treatment?
How do you manage patients blood pressures while on anti-angiogenic TKIs?
What is the role of post-transplant FLT3 inhibition given the results of BMT-CTN 1506 (MORPHO)?
Are there any circumstances where you would consider bridging for patients on DOACs?
What is your approach to cancer patients who inquire about alternative or complementary treatments?
What is your approach to treatment of infection-triggered HLH that does not respond to treatment of the underlying infection?
What is your approach to treating a young adult with severe aplastic anemia unresponsive to steroids and TPO-mimetics?
What additional testing is recommended with heterozygous HFE C282Y mutation whose ferritin is elevated and transferrin saturation percentage is at baseline?